Medtronic Dividend Expectations and Performance Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MDT?
Source: NASDAQ.COM
- Dividend Yield Analysis: Medtronic (MDT) currently has an annualized dividend yield of 3.25%, and while dividends are not always predictable, historical data suggests this yield may remain stable, indicating the company's commitment to its dividend policy.
- Stock Price Range: MDT shares have a 52-week low of $79.55 and a high of $106.33, with the latest trade at $86.79, demonstrating reasonable price fluctuations that may attract investor interest.
- ETF Composition: According to ETF Finder, MDT comprises 4.57% of the iShares U.S. Medical Devices ETF (IHI), which is trading up about 1.2% on the day, reflecting positive market sentiment towards the medical devices sector.
- Intraday Trading Performance: On Wednesday, Medtronic shares rose approximately 0.9%, indicating a positive short-term outlook from the market, which may reflect investor confidence in the company's growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 87.140
Low
102.00
Averages
111.76
High
120.00
Current: 87.140
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
Medtronic's Robot-Assisted Surgical System Approved by FDA
- FDA Approval: Medtronic's Stealth AXiS robot-assisted surgical system has received FDA approval for cranial and ENT procedures, marking a significant advancement in the company's medical robotics portfolio.
- Technology Integration: The system integrates preoperative planning, surgical navigation, and robotics, based on technologies from Mazor Robotics, which Medtronic acquired for $1.6 billion in 2019, enhancing surgeon workflows and procedural efficiency.
- Market Outlook: Having received FDA clearance for spine procedures last month, the expansion to cranial and ENT applications is expected to further strengthen Medtronic's competitive position in the robotic surgery market.
- Expert Commentary: Vijay Ramakrishnan, a professor at Indiana University School of Medicine, highlighted that the system enhances surgeon confidence and efficiency through innovative technologies, potentially transforming operating room workflows.
See More
Medtronic Launches Stealth AXiS™ Surgical System for Enhanced Precision
- FDA Clearance: Medtronic's Stealth AXiS™ surgical system has received FDA clearance for cranial and ENT procedures, marking a significant innovation in healthcare technology that is expected to enhance surgical precision and efficiency.
- Intelligent Surgical Platform: The system integrates surgical planning, navigation, and robotics, utilizing an AI-enabled architecture to provide real-time insights for surgeons, thereby improving decision-making during complex procedures and enhancing patient outcomes.
- Breakthrough for ENT Surgery: The Stealth AXiS™ system delivers high-precision navigation and advanced visualization for ENT surgeries, optimizing surgical workflows and boosting surgeons' confidence in high-risk areas, which is anticipated to drive technological advancements in the field.
- Continuous Innovation Capability: The system's flexible architecture supports ongoing software innovation and expanded functionalities, aiming to shape the next era of surgery and further solidify Medtronic's leadership position in the global healthcare technology market.
See More
5 Spin-Off Stocks That May Benefit Patient Investors by 2026
Spin-offs as Business Tools: Spin-offs are effective for businesses, allowing them to focus on growth and enhance shareholder value by separating ongoing operations into distinct entities.
FedEx Spin-off Insights: FedEx's spin-off suggests that both the original and new companies are likely to be valuable, with the freight business potentially trading at a premium due to market conditions.
KBR's Strategic Split: KBR plans to split its business to enhance focus on sustainable technology solutions, separating its government services from its core operations, which will allow for better financial flexibility and growth opportunities.
Honeywell's Focused Spin-off: Honeywell aims to split its aerospace business into a more focused unit, improving cash flow and operational efficiency while allowing the original business to concentrate on industrial automation.
See More
Medtronic Dividend Expectations and Performance Analysis
- Dividend Yield Analysis: Medtronic (MDT) currently has an annualized dividend yield of 3.25%, and while dividends are not always predictable, historical data suggests this yield may remain stable, indicating the company's commitment to its dividend policy.
- Stock Price Range: MDT shares have a 52-week low of $79.55 and a high of $106.33, with the latest trade at $86.79, demonstrating reasonable price fluctuations that may attract investor interest.
- ETF Composition: According to ETF Finder, MDT comprises 4.57% of the iShares U.S. Medical Devices ETF (IHI), which is trading up about 1.2% on the day, reflecting positive market sentiment towards the medical devices sector.
- Intraday Trading Performance: On Wednesday, Medtronic shares rose approximately 0.9%, indicating a positive short-term outlook from the market, which may reflect investor confidence in the company's growth potential.
See More
Medtronic Lowers Full-Year Earnings Outlook Amid MiniMed IPO
- Earnings Outlook Downgrade: Medtronic (MDT) has lowered its non-GAAP earnings per share forecast for fiscal 2026 to $5.50 - $5.54 from a previous range of $5.62 - $5.66 due to the recent IPO of its diabetes business MiniMed Group (MMED), indicating significant pressure on profitability.
- IPO Impact Analysis: The public listing of MiniMed (MMED) on March 9 is expected to create a $0.04 per share dilutive effect for Medtronic (MDT), highlighting the direct financial implications of the new listing and potentially undermining investor confidence.
- One-Time Expense Burden: MiniMed (MMED) will incur a one-time charge of $157 million due to payments owed to Blackstone (BX), which will impact earnings by $0.08 per share in Q4 FY26, further exacerbating the company's financial challenges.
- Future Growth Outlook: Despite the current earnings downgrade, Medtronic (MDT) maintains its outlook for high single-digit EPS growth for fiscal 2027, reflecting confidence in the company's long-term growth potential.
See More
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
Medtronic's Robot-Assisted Surgical System Approved by FDA
- FDA Approval: Medtronic's Stealth AXiS robot-assisted surgical system has received FDA approval for cranial and ENT procedures, marking a significant advancement in the company's medical robotics portfolio.
- Technology Integration: The system integrates preoperative planning, surgical navigation, and robotics, based on technologies from Mazor Robotics, which Medtronic acquired for $1.6 billion in 2019, enhancing surgeon workflows and procedural efficiency.
- Market Outlook: Having received FDA clearance for spine procedures last month, the expansion to cranial and ENT applications is expected to further strengthen Medtronic's competitive position in the robotic surgery market.
- Expert Commentary: Vijay Ramakrishnan, a professor at Indiana University School of Medicine, highlighted that the system enhances surgeon confidence and efficiency through innovative technologies, potentially transforming operating room workflows.
See More
Medtronic Launches Stealth AXiS™ Surgical System for Enhanced Precision
- FDA Clearance: Medtronic's Stealth AXiS™ surgical system has received FDA clearance for cranial and ENT procedures, marking a significant innovation in healthcare technology that is expected to enhance surgical precision and efficiency.
- Intelligent Surgical Platform: The system integrates surgical planning, navigation, and robotics, utilizing an AI-enabled architecture to provide real-time insights for surgeons, thereby improving decision-making during complex procedures and enhancing patient outcomes.
- Breakthrough for ENT Surgery: The Stealth AXiS™ system delivers high-precision navigation and advanced visualization for ENT surgeries, optimizing surgical workflows and boosting surgeons' confidence in high-risk areas, which is anticipated to drive technological advancements in the field.
- Continuous Innovation Capability: The system's flexible architecture supports ongoing software innovation and expanded functionalities, aiming to shape the next era of surgery and further solidify Medtronic's leadership position in the global healthcare technology market.
See More
5 Spin-Off Stocks That May Benefit Patient Investors by 2026
Spin-offs as Business Tools: Spin-offs are effective for businesses, allowing them to focus on growth and enhance shareholder value by separating ongoing operations into distinct entities.
FedEx Spin-off Insights: FedEx's spin-off suggests that both the original and new companies are likely to be valuable, with the freight business potentially trading at a premium due to market conditions.
KBR's Strategic Split: KBR plans to split its business to enhance focus on sustainable technology solutions, separating its government services from its core operations, which will allow for better financial flexibility and growth opportunities.
Honeywell's Focused Spin-off: Honeywell aims to split its aerospace business into a more focused unit, improving cash flow and operational efficiency while allowing the original business to concentrate on industrial automation.
See More
Medtronic Dividend Expectations and Performance Analysis
- Dividend Yield Analysis: Medtronic (MDT) currently has an annualized dividend yield of 3.25%, and while dividends are not always predictable, historical data suggests this yield may remain stable, indicating the company's commitment to its dividend policy.
- Stock Price Range: MDT shares have a 52-week low of $79.55 and a high of $106.33, with the latest trade at $86.79, demonstrating reasonable price fluctuations that may attract investor interest.
- ETF Composition: According to ETF Finder, MDT comprises 4.57% of the iShares U.S. Medical Devices ETF (IHI), which is trading up about 1.2% on the day, reflecting positive market sentiment towards the medical devices sector.
- Intraday Trading Performance: On Wednesday, Medtronic shares rose approximately 0.9%, indicating a positive short-term outlook from the market, which may reflect investor confidence in the company's growth potential.
See More
Medtronic Lowers Full-Year Earnings Outlook Amid MiniMed IPO
- Earnings Outlook Downgrade: Medtronic (MDT) has lowered its non-GAAP earnings per share forecast for fiscal 2026 to $5.50 - $5.54 from a previous range of $5.62 - $5.66 due to the recent IPO of its diabetes business MiniMed Group (MMED), indicating significant pressure on profitability.
- IPO Impact Analysis: The public listing of MiniMed (MMED) on March 9 is expected to create a $0.04 per share dilutive effect for Medtronic (MDT), highlighting the direct financial implications of the new listing and potentially undermining investor confidence.
- One-Time Expense Burden: MiniMed (MMED) will incur a one-time charge of $157 million due to payments owed to Blackstone (BX), which will impact earnings by $0.08 per share in Q4 FY26, further exacerbating the company's financial challenges.
- Future Growth Outlook: Despite the current earnings downgrade, Medtronic (MDT) maintains its outlook for high single-digit EPS growth for fiscal 2027, reflecting confidence in the company's long-term growth potential.
See More
